The establishment of Duchenne Network Australia is an encouraging example of ACTA’s grow, strengthen and support investigator-initiated clinical trials mission in action.
This new CTN is a program of Save our Sons Duchenne Foundation the formation of which ACTA’s CTN Sector Expansion Reference Group facilitated, including a presentation by Prof Chris Maher from recent experience establishing the Australian and New Zealand Alliance for Cardiovascular Trials network (ANZACT).
Meanwhile, conversations continue with people from across the healthcare sector as the Reference Group progresses its work to identify and connect existing clinical trial networks and is ready to facilitate network expansion or establishment of new networks to fill clinical-need gaps.
At the ACTA Summit, Prof Rachelle Buchbinder of Monash University and ANZMUSC CTN, and The George Institute’s Prof Anushka Patel will share their experience from establishing new clinical trial networks: musculoskeletal and cardiovascular trials, respectively, and Menzies School of Health Research Director, Prof Alan Cass, will reflect on challenges and successes in Aboriginal and Torres Strait Islander clinical research.